BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  San Diego’s Mirati Therapeutics Abandons Lead Drug, Shifts Focus

  Two months after positive preliminary data showed sitravatinib in combination with Opdivo demonstrated some efficacy in treating patients with NSCLC, Mirati said it will reprioritize its R&D to focus.

  November 13, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Gates Pledges $100M to the Holy Grail of Science--Alzheimer’s

  Gates to invest $50 million in the Dementia Discovery Fund and another $50 million in a number of start-up ventures working on Alzheimer’s research.

  November 13, 2017

   · 

  1 min read
• 

  Biotech Bay

  Bay Area’s Arcus Biosciences Scores $107M, Initiates Two Clinical Trials

  Now totaling $227M, Arcus Biosciences announced it had closed a $107M Series C financing.

  November 13, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Job Trends

  Pfizer to Hire Up to 400 in Michigan for 2018

  Pfizer is planning to hire 200 new staffers and another 200 replacement workers in Michigan.

  November 13, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  BioMidwest

  Medtronic’s Insulin Pump Dominance Boosted by Johnson & Johnson’s Exit

  Good news seems to keep coming for medtech company Medtronic.

  November 13, 2017

   · 

  2 min read

   · 

  Alex Keown
• Deals

  Week in Review: China’s Creat to Restructure $1.5B Biotest Takeover

  Creat Group will attempt to restructure its $1.5M offer to acquire Biotest after U.S. regulators nixed the deal.

  November 13, 2017

   · 

  1 min read
• Drug Development

  Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting

  Five Prime is developing FPA144, an isoform-selective antibody, as a targeted immunotherapy for tumors that overexpress FGFR2b.

  November 13, 2017

   · 

  3 min read
• Business

  CombiMatrix Corporation Stockholders Approve Merger Agreement With Invitae Corporation

  Approximately 1.79 million of the common shares voting at today’s Special Meeting voted in favor of the approval and adoption of the all-stock merger agreement.

  November 13, 2017

   · 

  6 min read
• Drug Development

  Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection

  Results showed a response rate of 14 percent (two partial responses, one of which was unconfirmed) with single agent CPI-444 and 13 percent (two confirmed partial responses) for the combination therapy.

  November 13, 2017

   · 

  11 min read
• Genetown

  CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting

  CRISPR believes that its CAR-T cells therapies may have distinct advantages over the current generation of autologous cell therapies.

  November 13, 2017

   · 

  6 min read